For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Multiple clones. Multiple opportunities. One purchase.
Immune checkpoints are critical molecules that modulate the T-cell-stimulatory signals of the immune response1. Since many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies, providing a promising approach to activating therapeutic antitumor immunity2.
Discover our range of hand-picked antibody panels to key immuno-oncology targets designed to save you time and provide you with easy access to the best selection of clones on the market. Each panel contains a selection of monoclonal antibodies that detect the same protein to increase your chances of finding a compatible clone for your assay with just one purchase.
We eliminate the need for pre-screening by narrowing our catalog to the most suitable, IHC-optimized clones and packaging into an easily accessible kit so you can get on with determining the best antibody for your IHC research assay needs.
Recent studies have highlighted that TIM-3 has an important role to play in T-cell exhaustion and correlates with the outcome of anti-PD-1 therapy, therefore targeting TIM-3 might be a promising approach for cancer immunotherapy3.
Our TIM-3 antibody panel contains three recombinant monoclonal antibodies against human TIM-3.
LAG-3 ensures immune homeostasis through suppressing T-cell activation and cytokine secretion. Immunotherapies targeting LAG-3 are moving forward into clinical trials, and combination immunotherapy of anti-LAG-3 and anti-PD-1 is showing promising efficacy in overcoming resistance to PD-1 immunotherapy4.
Our LAG-3 antibody panel contains six recombinant monoclonal antibodies to human LAG-3.
GITR is a co-stimulatory cell surface receptor which is expressed by T-cells and natural killer cells. GITR modulation in preclinical models has shown promising antitumor activity by stimulating effector T-cells and suppressing regulatory T-cells5.
Our GITR antibody panel contains three recombinant monoclonal antibodies to human GITR.
The PD-1/PD-L1 pathway plays a key role in physiological immune homeostasis and provide a means through which cancer can evade the immune system. The development and application of immune checkpoint inhibitors that block PD-1/PD-L1 interaction result in very durable responses in a wide range of cancers and prolong survival in a subset of patients6 .
Our PD-L1 antibody panel contains four recombinant monoclonal antibodies to human PD-L1 including highly cited and best-in-class clones 28-8, SP142, and 73-10.
PD-1 is the receptor to transmembrane ligand PD-L1 and is expressed on the surface of T-cells. Cancer cells may exploit the PD-1/PD-L1 interaction to evade and suppress the immune response. Inhibition of the PD-1 pathway is increasingly being adopted as a therapeutic approach to treat cancers7.
Our PD-1 antibody panel contains five monoclonal antibodies to human PD-1 including the top-cited NAT105 clone.
Once you have established the best clone for your assay, get in contact to start the conversation on how we can support you through your pipeline with flexible formats, scale-up options, custom conjugations, and support for commercial partnerships.
6. Rizvi, Naiyer A et al. “Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.” The Lancet. Oncology vol. 16,3 (2015): 257-65.